LILRB4

LILRB4 Overview

English NameLeukocyte immunoglobulin-like receptor subfamily B member 4Approved Drugs0
Drugs in Clinical Trials7Target SynonymCD85k Antigen,Leukocyte immunoglobulin-like receptor 5,Immunoglobulin-like transcript 3,CD85k,CD85 antigen-like family member K,LIR-5,Monocyte inhibitory receptor HM18,ILT-3,Leucocyte Ig-Like Receptor B4,ILT3,LIR5,Leukocyte Immunoglobulin-Like Receptor, Subfamily B (With TM And ITIM Domains), Member 4,HM18,Leukocyte Immunoglobulin Like Receptor B4
Highest Development StagePhase 2 Clinical
English NameLeukocyte immunoglobulin-like receptor subfamily B member 4
Target SynonymCD85k Antigen,Leukocyte immunoglobulin-like receptor 5,Immunoglobulin-like transcript 3,CD85k,CD85 antigen-like family member K,LIR-5,Monocyte inhibitory receptor HM18,ILT-3,Leucocyte Ig-Like Receptor B4,ILT3,LIR5,Leukocyte Immunoglobulin-Like Receptor, Subfamily B (With TM And ITIM Domains), Member 4,HM18,Leukocyte Immunoglobulin Like Receptor B4
Approved Drugs0
Drugs in Clinical Trials7
Highest Development StagePhase 2 Clinical

LILRB4 Background

Leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4) is also known as CD85 antigen-like family member K (CD85K), Immunoglobulin-like transcript 3 (ILT-3), Leukocyte immunoglobulin-like receptor 5 (LIR-5), Monocyte inhibitory receptor HM18, which belongs to the leukocyte immunoglobulin-like receptor (LIR) family. LILRB4 / CD85K contains 2 Ig-like C2-type (immunoglobulin-like) domains. CD85K is detected in monocytes, macrophages, dendritic cells, lung, natural killer cells and B-cells. LILRB4 / CD85K is receptor for class I MHC antigens. CD85K recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles, involved in the down-regulation of the immune response and the development of tolerance. LILRB4 interferes with TNFRSF5-signaling and NF-kappa-B up-regulation and inhibits receptor-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions.

LILRB4 Synonyms

LILRB4,ILT3,LIR5,CD85K,HM18

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
MK-0482MK-0482Phase 2 ClinicalMerck Sharp & Dohme CorpCarcinoma, Non-Small-Cell Lung; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Neoplasms; Sarcoma; Squamous Cell Carcinoma of Head and Neck
Details
IO-202IO-202Phase 1 ClinicalYiming Biomedical Technology (Hangzhou) Co LtdLeukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Solid tumours
Details
anti-ILT3 CAR T-cell therapy (Carbiogene Therapeutics)Phase 1 ClinicalCarbiogene Therapeutics Co LtdLeukemia, Myeloid, Acute
Details
YTS-104LILRB4 STAR-T; YTS-104Phase 1 ClinicalBeijing Qingyi Taike Pharmaceutical Technology Co Ltd, China Immunotech Co LtdLeukemia, Myeloid
Details
BND-35BND-35; BND35Phase 1 ClinicalBiond Biologics LtdNeoplasms; Solid tumours
Details
NGM-831NGM-831Phase 1 ClinicalNGM Biopharmaceuticals IncBreast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Neoplasms; Melanoma; Mesothelioma; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Uterine Cervical Neoplasms
Details
anti-ILT3 CAR-T Therapy(Carbiogene)Phase 1 ClinicalCarbiogene Therapeutics Co LtdLeukemia, Myeloid, Acute
Details
  • Overview
  • Product List
  • Clinical Drug Information
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland